Table 4.
CAZ | ERT | MEM | GEN | |
---|---|---|---|---|
E. coli ATCC 25922 | 0.5 (S) | 0.016 (S) | 0.03 (S) | 0.5 (S) |
E. coli M19736 | 0.03 (S) | 0.5 (S) | 0.25 (S) | 0.03 (S) |
E. coli J53 | 0.25 (S) | 0.08 (S) | 0.03 (S) | 0.5 (S) |
E. coli SM5 | 64 (R) | 0.12 (S) | 0.06 (S) | 0.5 (S) |
E. coli M19736::pDCAG1-CTX-M-15 | >64 (R) | 0.5 (S) | 0.25 (S) | 0.03 (S) |
E. coli J53::pDCAG1-CTX-M-15 | 64 (R) | 0.08 (S) | 0.03 (S) | 0.5 (S) |
K pneumoniae HA7Kp | 32 (R) | 8 (R) | 8 (R) | 0.25 (S) |
E. coli M19736::pDCCK1-KPC | 32 (R) | 4 (R) | 2 (I) | 0.03 (S) |
E. coli J53::pDCCK1-KPC | 16 (R) | 2 (R) | 4 (R) | 0.5 (S) |
K. pneumoniae HA31Kp | >64 (R) | 32 (R) | 32 (R) | >64 (R) |
E. coli M19736::pDCVA3-NDM-5 | >64 (R) | 64 (R) | 32 (R) | 0.03 (S) |
E. coli J53::pDCVA3-NDM-5 | >64 (R) | 2 (R) | 4 (R) | 0.5 (S) |
S. marcescens SM938 | >64 (R) | 8 (R) | 8 (R) | 2 (S) |
E. coli M19736::pDCASG-NDM-1 | >64 (R) | 16 (R) | 8 (R) | 0.03 (S) |
E. coli J53::pDCASG-NDM-1 | >64 (R) | 32 (R) | 16 (R) | 0.5 (S) |
Evolved MDR-E. coli M19736 | >64 (R) | 32 (R) | 16 (R) | 0.03 (S) |
Evolved XDR-E. coli M19736 | >64 (R) | 32 (R) | 16 (R) | 32 (R) |
Results were interpreted according to the Clinical and Laboratory Standards Institute guidelines (CLSI, 2023).
CAZ, ceftazidime; ERT, ertapenem; MEM, meropenem; GEN, gentamicin. Interpretation results: I, intermediate; R, resistance; S, susceptible.